Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.32 |
| ▸ | CDK2 | P24941 | 8/20 | 0.32 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NTMT1 | Q9BV86 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25519258 | 1.00 | GAA (0.33) | GAASSTR4CCNE1CDK2GSK3B | |
| SCHEMBL25519260 | 0.86 | EPHX1 (0.36) | SSTR4NTMT1LMNA | |
| SCHEMBL20998179 | 0.86 | CHRM1 (0.38) | — | |
| SCHEMBL25519261 | 0.81 | CDK2 (0.37) | CCNE1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL25519241 | 0.81 | CHRM2 (0.34) | — | |
| SCHEMBL19220263 | 0.81 | CHRM2 (0.34) | — | |
| SCHEMBL25519601 | 0.80 | TSHR (0.37) | SSTR4SMN1; SMN2LMNA | |
| SCHEMBL25519242 | 0.80 | GPR119 (0.38) | — | |
| SCHEMBL25519266 | 0.78 | CNR2 (0.31) | — | |
| SCHEMBL29215627 | 0.78 | EPHX2 (0.36) | GAASSTR4SMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381761-A1 | CATALYSTS AND THEIR USES IN ONE-POT DIASTEREOSELECTIVE SYNTHESIS OF REMDESIVIR | ACADEMIA SINICA (TW) | 2023-11-30 | — | — | US | disclosed |
| US-10597422-B2 | Process for making chloro-substituted nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144485-A1 | Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds | MERCK SHARP & DOHME LLC | 2019-05-16 | — | — | US | disclosed |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144485-A1 | Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds | NUDT1, PNP, SAMHD1 | GAA 518/4885SSTR4 3715/4885CCNE1 555/4885 |
| US-20170226146-A1 | PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS | NUDT1, PNP, SAMHD1 | GAA 518/4885SSTR4 3715/4885CCNE1 555/4885 |
| US-20230381761-A1 | CATALYSTS AND THEIR USES IN ONE-POT DIASTEREOSELECTIVE SYNTHESIS OF REMDESIVIR | MTAP, PNP, ALKBH1 | GAA 33/4885SSTR4 4675/4885CCNE1 4249/4885 |
| US-10597422-B2 | Process for making chloro-substituted nucleoside phosphoramidate compounds | NUDT1, PNP, SAMHD1 | GAA 518/4885SSTR4 3715/4885CCNE1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.